Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims

Lab Test Company Did Not Conduct Data Analysis

 
• By Andrew McConaghie
  
Cassava Sciences
Cassava has seen its share price dive as the claims behind its small molecule therapy come under increasing scrutiny.

More from Business

More from Scrip